KR100589545B1 - 관절염의 치료를 위한 옥사졸리디논 유도체의 용도 - Google Patents

관절염의 치료를 위한 옥사졸리디논 유도체의 용도 Download PDF

Info

Publication number
KR100589545B1
KR100589545B1 KR1020057017426A KR20057017426A KR100589545B1 KR 100589545 B1 KR100589545 B1 KR 100589545B1 KR 1020057017426 A KR1020057017426 A KR 1020057017426A KR 20057017426 A KR20057017426 A KR 20057017426A KR 100589545 B1 KR100589545 B1 KR 100589545B1
Authority
KR
South Korea
Prior art keywords
oxazolidinone
acetamide
oxazolidinyl
oxo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057017426A
Other languages
English (en)
Korean (ko)
Other versions
KR20050100009A (ko
Inventor
도널드 에이치. 바츠
로저 지. 율리히
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20050100009A publication Critical patent/KR20050100009A/ko
Application granted granted Critical
Publication of KR100589545B1 publication Critical patent/KR100589545B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057017426A 1997-11-18 1998-11-10 관절염의 치료를 위한 옥사졸리디논 유도체의 용도 Expired - Fee Related KR100589545B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US6568997P 1997-11-18 1997-11-18
US60/065,689 1997-11-18
US7129798P 1998-01-16 1998-01-16
US60/071,297 1998-01-16
US7366298P 1998-02-04 1998-02-04
US60/073,662 1998-02-04
US7524798P 1998-02-19 1998-02-19
US60/075,247 1998-02-19
US7767298P 1998-03-12 1998-03-12
US60/077,672 1998-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020007005366A Division KR100574307B1 (ko) 1997-11-18 1998-11-10 건선의 치료를 위한 옥사졸리디논 유도체의 용도

Publications (2)

Publication Number Publication Date
KR20050100009A KR20050100009A (ko) 2005-10-17
KR100589545B1 true KR100589545B1 (ko) 2006-06-19

Family

ID=27535698

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057017426A Expired - Fee Related KR100589545B1 (ko) 1997-11-18 1998-11-10 관절염의 치료를 위한 옥사졸리디논 유도체의 용도
KR1020007005366A Expired - Fee Related KR100574307B1 (ko) 1997-11-18 1998-11-10 건선의 치료를 위한 옥사졸리디논 유도체의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020007005366A Expired - Fee Related KR100574307B1 (ko) 1997-11-18 1998-11-10 건선의 치료를 위한 옥사졸리디논 유도체의 용도

Country Status (15)

Country Link
EP (1) EP1032386B1 (https=)
JP (1) JP2001522886A (https=)
KR (2) KR100589545B1 (https=)
CN (2) CN1546030A (https=)
AT (1) ATE233092T1 (https=)
AU (1) AU743941B2 (https=)
BR (1) BR9815615A (https=)
CA (1) CA2303961A1 (https=)
DE (1) DE69811717T2 (https=)
DK (1) DK1032386T3 (https=)
ES (1) ES2193592T3 (https=)
NZ (1) NZ504612A (https=)
PT (1) PT1032386E (https=)
SI (1) SI1032386T1 (https=)
WO (1) WO1999025344A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003595T2 (tr) 1998-06-05 2001-07-23 Astrazeneca Ab Kimyasal bileşikler
ATE337002T1 (de) * 1999-09-13 2006-09-15 Insite Vision Inc Topische behandlung zur vorbeugung von augeninfektionen
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones

Also Published As

Publication number Publication date
AU743941B2 (en) 2002-02-07
CN1546030A (zh) 2004-11-17
WO1999025344A1 (en) 1999-05-27
DE69811717T2 (de) 2003-10-16
CN1299281A (zh) 2001-06-13
EP1032386B1 (en) 2003-02-26
KR20050100009A (ko) 2005-10-17
DE69811717D1 (de) 2003-04-03
KR100574307B1 (ko) 2006-04-27
ATE233092T1 (de) 2003-03-15
KR20010032178A (ko) 2001-04-16
AU1582399A (en) 1999-06-07
SI1032386T1 (en) 2003-06-30
NZ504612A (en) 2002-08-28
BR9815615A (pt) 2000-10-24
JP2001522886A (ja) 2001-11-20
PT1032386E (pt) 2003-07-31
CA2303961A1 (en) 1999-05-27
DK1032386T3 (da) 2003-05-26
CN1142777C (zh) 2004-03-24
HK1036591A1 (en) 2002-01-11
EP1032386A1 (en) 2000-09-06
ES2193592T3 (es) 2003-11-01

Similar Documents

Publication Publication Date Title
US6040306A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
WO2002036592A1 (en) Remedies for arachidonic acid-induced skin diseases
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
CZ283875B6 (cs) Kosolventní parenterální formulace tirilazadu
KR102317158B1 (ko) 항미생물 화합물, 조성물, 및 그의 용도
AU2011334592C1 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
KR100589545B1 (ko) 관절염의 치료를 위한 옥사졸리디논 유도체의 용도
EP2124930B1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
KR102784577B1 (ko) 인간 및 동물에서 알레르기 질환 및 다른 질환의 치료를 위한 말론산의 비스아미드 유도체의 용도
EA003274B1 (ru) Оксазолидиноны в качестве активного вещества при лечении инфекционных глазных болезней
EP1304107A2 (en) Use of oxazolidinines derivatives for treating psoriasis
US20260069585A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
AU780197B2 (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
JP2025504447A (ja) アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
MXPA00004807A (en) Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
AU9720601A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
CN108640916A (zh) 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物
HK1069768A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy background of the invention
US20260069553A1 (en) TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES
EP4561574A1 (en) Dosing regimen for a nlrp3 inhibitor
JPH07503243A (ja) エム・ファーメンタンス感染症の治療
JPH0228113A (ja) 高尿酸血症改善・治療剤
JP2003252793A (ja) 痔疾用医薬組成物
EP2179733A1 (en) Pharmaceutical composition combining an antimicrobial agent and a selective enkephalinase enzyme inhibitor, which can be used to control and treat acute bacterial diarrhoea

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20090608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090608

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000